The HIV protease inhibitor Saquinavir attenuates sepsis-induced acute lung injury and promotes M2 macrophage polarization via targeting matrix metalloproteinase-9.
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
11 01 2021
11 01 2021
Historique:
received:
21
05
2020
accepted:
06
11
2020
revised:
02
11
2020
entrez:
12
1
2021
pubmed:
13
1
2021
medline:
30
9
2021
Statut:
epublish
Résumé
Imbalance of macrophage polarization plays an indispensable role in acute lung injury (ALI), which is considered as a promising target. Matrix metalloproteinase-9 (MMP-9) is expressed in the macrophage, and has a pivotal role in secreting inflammatory cytokines. We reported that saquinavir (SQV), a first-generation human immunodeficiency virus-protease inhibitor, restricted exaggerated inflammatory response. However, whether MMP-9 could regulate macrophage polarization and inhibit by SQV is still unknown. We focused on the important role of macrophage polarization in CLP (cecal ligation puncture)-mediated ALI and determined the ability of SQV to maintain M2 over M1 phenotype partially through the inhibition of MMP-9. We also performed a limited clinical study to determine if MMP-9 is a biomarker of sepsis. Lipopolysaccharide (LPS) increased MMP-9 expression and recombinant MMP-9 (rMMP-9) exacerbated LPS-mediated M1 switching. Small interfering RNA to MMP-9 inhibited LPS-mediated M1 phenotype and SQV inhibition of this switching was reversed with rMMP-9, suggesting an important role for MMP-9 in mediating LPS-induced M1 phenotype. MMP-9 messenger RNA levels in peripheral blood mononuclear cells of these 14 patients correlated with their clinical assessment. There was a significant dose-dependent decrease in mortality and ALI after CLP with SQV. SQV significantly inhibited LPS-mediated M1 phenotype and increased M2 phenotype in cultured RAW 264.7 and primary murine bone marrow-derived macrophages as well as lung macrophages from CLP-treated mice. This study supports an important role for MMP-9 in macrophage phenotypic switching and suggests that SQV-mediated inhibition of MMP-9 may be involved in suppressing ALI during systemic sepsis.
Identifiants
pubmed: 33431821
doi: 10.1038/s41419-020-03320-0
pii: 10.1038/s41419-020-03320-0
pmc: PMC7798387
doi:
Substances chimiques
HIV Protease Inhibitors
0
Matrix Metalloproteinase 9
EC 3.4.24.35
Saquinavir
L3JE09KZ2F
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
67Références
Exp Mol Pathol. 2012 Jun;92(3):287-95
pubmed: 22421441
Shock. 2015 Aug;44(2):128-36
pubmed: 26009816
Int J Biol Sci. 2014 May 01;10(5):520-9
pubmed: 24910531
J Surg Res. 2003 May 15;111(2):185-95
pubmed: 12850461
World J Emerg Med. 2014;5(2):139-43
pubmed: 25215164
Scand J Infect Dis. 2003;35(9):585-92
pubmed: 14620139
J Thromb Haemost. 2013 Jul;11(7):1385-98
pubmed: 23617547
N Engl J Med. 2013 Aug 29;369(9):840-51
pubmed: 23984731
Lancet. 1995 Apr 15;345(8955):952-5
pubmed: 7715294
Circ Res. 2003 May 2;92(8):827-39
pubmed: 12730128
Cancer Res. 2002 Sep 15;62(18):5230-5
pubmed: 12234989
J Surg Res. 2001 Aug;99(2):245-52
pubmed: 11469893
J Immunol. 2008 Sep 15;181(6):3733-9
pubmed: 18768823
Am J Physiol Lung Cell Mol Physiol. 2008 Mar;294(3):L535-43
pubmed: 18223162
Crit Care Med. 1999 Feb;27(2):304-12
pubmed: 10075054
Thorax. 2006 Mar;61(3):259-66
pubmed: 16227332
Inflamm Bowel Dis. 2008 Apr;14(4):480-90
pubmed: 18095317
PLoS One. 2014 Apr 10;9(4):e94701
pubmed: 24722316
AIDS. 2012 May 15;26(8):909-19
pubmed: 22313963
Shock. 2015 Apr;43(4):352-60
pubmed: 25526379
Am J Respir Crit Care Med. 1997 Jan;155(1):43-6
pubmed: 9001287
Proc Natl Acad Sci U S A. 2016 Dec 13;113(50):E8151-E8158
pubmed: 27911817
Am J Physiol Lung Cell Mol Physiol. 2006 Oct;291(4):L580-7
pubmed: 16698855
Mucosal Immunol. 2010 May;3(3):291-300
pubmed: 20404812
Arterioscler Thromb Vasc Biol. 2015 Dec;35(12):2579-93
pubmed: 26515416
J Leukoc Biol. 2001 Jun;69(6):851-9
pubmed: 11404367
Am J Respir Cell Mol Biol. 2001 May;24(5):537-44
pubmed: 11350822
Crit Care Med. 2003 Feb;31(2):536-42
pubmed: 12576963
Nat Immunol. 2011 Jul 19;12(8):695-708
pubmed: 21772278
Mol Med. 2017 Jun;23:92-100
pubmed: 28332696
PLoS One. 2013 Jun 14;8(6):e65994
pubmed: 23799067
Cancer Res. 2002 Dec 1;62(23):6901-8
pubmed: 12460905
Nat Med. 2002 Mar;8(3):225-32
pubmed: 11875492
J Exp Med. 2008 Dec 22;205(13):3065-77
pubmed: 19064696
Blood. 2013 Dec 12;122(25):4054-67
pubmed: 24174628
J Leukoc Biol. 2007 Dec;82(6):1375-81
pubmed: 17709402
Mol Med Rep. 2015 Jul;12(1):753-9
pubmed: 25738807
Nat Immunol. 2017 Sep;18(9):985-994
pubmed: 28714978
J Int Med Res. 2012;40(1):115-25
pubmed: 22429351
Am J Respir Crit Care Med. 1998 Jan;157(1):263-72
pubmed: 9445308
J Crit Care. 2011 Dec;26(6):556-65
pubmed: 21439766
Pediatr Infect Dis J. 2013 Apr;32(4):350-3
pubmed: 23190774
Front Immunol. 2011 Nov 24;2:65
pubmed: 22566854
J Neuroimmunol. 2001 Aug 30;118(2):233-44
pubmed: 11498258
Mol Med. 2015 Dec;21(1):749-757
pubmed: 26349060
Acta Pharmacol Sin. 2008 Jul;29(7):847-52
pubmed: 18565283
Environ Health Perspect. 2007 Nov;115(11):1557-63
pubmed: 18007984
J Exp Med. 2015 Jan 12;212(1):5-14
pubmed: 25559892
Am J Respir Crit Care Med. 2005 Oct 1;172(7):798-806
pubmed: 16020801
J Clin Invest. 2005 Jul;115(7):1828-38
pubmed: 15937550